APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK1/NK3 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global NK1/NK3 Receptor Antagonists Market Analysis and Forecast 2026-2032

23 December 2025200 pages

Choose your research edition.

Industry ResearchNK1/NK3 Receptor Antagonists Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal NK1/NK3 Receptor Antagonists Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal NK1/NK3 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK1/NK3 Receptor Antagonists Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal NK1/NK3 Receptor Antagonists Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global NK1/NK3 Receptor Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for NK1/NK3 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for NK1/NK3 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for NK1/NK3 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for NK1/NK3 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of NK1/NK3 Receptor Antagonists include Chia Tai Tianqing Pharmaceutical, Yichang Humanwell Pharmaceutical, Qilu Pharmaceutical, Merck, Luoxin Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Helsinn Healthcare, Hansoh Pharma and Fresenius Kabi, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for NK1/NK3 Receptor Antagonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of NK1/NK3 Receptor Antagonists, also provides the sales of main regions and countries. Of the upcoming market potential for NK1/NK3 Receptor Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the NK1/NK3 Receptor Antagonists sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global NK1/NK3 Receptor Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for NK1/NK3 Receptor Antagonists sales, projected growth trends, production technology, application and end-user industry.

NK1/NK3 Receptor Antagonists Segment by Company

Chia Tai Tianqing Pharmaceutical

Yichang Humanwell Pharmaceutical

Qilu Pharmaceutical

Merck

Luoxin Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Helsinn Healthcare

Hansoh Pharma

Fresenius Kabi

Beijing Sihuan Pharmaceutical

Bayer

Astellas

Torrent Pharmaceuticals

TerSera Therapeutics

Heron Therapeutics

Glenmark

NK1/NK3 Receptor Antagonists Segment by Type

NK1 Receptor Antagonist

NK3 Receptor Antagonist

Dual Antagonist

NK1/NK3 Receptor Antagonists Segment by Application

Hospital

Specialty Clinic

NK1/NK3 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1/NK3 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK1/NK3 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1/NK3 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of NK1/NK3 Receptor Antagonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of NK1/NK3 Receptor Antagonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NK1/NK3 Receptor Antagonists sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global NK1/NK3 Receptor Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NK1 Receptor Antagonist Major Manufacturers Table 3. NK3 Receptor Antagonist Major Manufacturers Table 4. Dual Antagonist Major Manufacturers Table 5. Global NK1/NK3 Receptor Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Manufacturers Table 7. Specialty Clinic Major Manufacturers Table 8. NK1/NK3 Receptor Antagonists Industry Trends Table 9. NK1/NK3 Receptor Antagonists Industry Drivers Table 10. NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges Table 11. NK1/NK3 Receptor Antagonists Industry Restraints Table 12. Global NK1/NK3 Receptor Antagonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global NK1/NK3 Receptor Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 14. Global NK1/NK3 Receptor Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 15. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2021-2026) Table 16. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2027-2032) Table 17. Global NK1/NK3 Receptor Antagonists Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026) & (k units) Table 19. Global NK1/NK3 Receptor Antagonists Sales by Region (2027-2032) & (k units) Table 20. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 21. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2027-2032) Table 22. Global NK1/NK3 Receptor Antagonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Manufacturers (2021-2026) Table 24. Global NK1/NK3 Receptor Antagonists Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global NK1/NK3 Receptor Antagonists Sales Market Share by Manufacturers (2021-2026) Table 26. Global NK1/NK3 Receptor Antagonists Sales Price (USD/unit) of Manufacturers (2021-2026) Table 27. Global NK1/NK3 Receptor Antagonists Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global NK1/NK3 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global NK1/NK3 Receptor Antagonists Manufacturers, Product Type & Application Table 30. Global NK1/NK3 Receptor Antagonists Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global NK1/NK3 Receptor Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global NK1/NK3 Receptor Antagonists Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 35. Global NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 36. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2026) Table 37. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2027-2032) Table 38. Global NK1/NK3 Receptor Antagonists Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 40. Global NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 41. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2026) Table 42. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2027-2032) Table 43. Global NK1/NK3 Receptor Antagonists Price by Type (2021-2026) & (USD/unit) Table 44. Global NK1/NK3 Receptor Antagonists Price by Type (2027-2032) & (USD/unit) Table 45. Global NK1/NK3 Receptor Antagonists Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 47. Global NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 48. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2026) Table 49. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2027-2032) Table 50. Global NK1/NK3 Receptor Antagonists Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 52. Global NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 53. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2026) Table 54. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2027-2032) Table 55. Global NK1/NK3 Receptor Antagonists Price by Application (2021-2026) & (USD/unit) Table 56. Global NK1/NK3 Receptor Antagonists Price by Application (2027-2032) & (USD/unit) Table 57. Chia Tai Tianqing Pharmaceutical Company Information Table 58. Chia Tai Tianqing Pharmaceutical Business Overview Table 59. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 60. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 61. Chia Tai Tianqing Pharmaceutical Recent Development Table 62. Yichang Humanwell Pharmaceutical Company Information Table 63. Yichang Humanwell Pharmaceutical Business Overview Table 64. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 65. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 66. Yichang Humanwell Pharmaceutical Recent Development Table 67. Qilu Pharmaceutical Company Information Table 68. Qilu Pharmaceutical Business Overview Table 69. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 70. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 71. Qilu Pharmaceutical Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Merck NK1/NK3 Receptor Antagonists Product Portfolio Table 76. Merck Recent Development Table 77. Luoxin Pharmaceutical Company Information Table 78. Luoxin Pharmaceutical Business Overview Table 79. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 81. Luoxin Pharmaceutical Recent Development Table 82. Jiangsu Hengrui Pharmaceuticals Company Information Table 83. Jiangsu Hengrui Pharmaceuticals Business Overview Table 84. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 86. Jiangsu Hengrui Pharmaceuticals Recent Development Table 87. Helsinn Healthcare Company Information Table 88. Helsinn Healthcare Business Overview Table 89. Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio Table 91. Helsinn Healthcare Recent Development Table 92. Hansoh Pharma Company Information Table 93. Hansoh Pharma Business Overview Table 94. Hansoh Pharma NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio Table 96. Hansoh Pharma Recent Development Table 97. Fresenius Kabi Company Information Table 98. Fresenius Kabi Business Overview Table 99. Fresenius Kabi NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio Table 101. Fresenius Kabi Recent Development Table 102. Beijing Sihuan Pharmaceutical Company Information Table 103. Beijing Sihuan Pharmaceutical Business Overview Table 104. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 106. Beijing Sihuan Pharmaceutical Recent Development Table 107. Bayer Company Information Table 108. Bayer Business Overview Table 109. Bayer NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Bayer NK1/NK3 Receptor Antagonists Product Portfolio Table 111. Bayer Recent Development Table 112. Astellas Company Information Table 113. Astellas Business Overview Table 114. Astellas NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Astellas NK1/NK3 Receptor Antagonists Product Portfolio Table 116. Astellas Recent Development Table 117. Torrent Pharmaceuticals Company Information Table 118. Torrent Pharmaceuticals Business Overview Table 119. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 121. Torrent Pharmaceuticals Recent Development Table 122. TerSera Therapeutics Company Information Table 123. TerSera Therapeutics Business Overview Table 124. TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 126. TerSera Therapeutics Recent Development Table 127. Heron Therapeutics Company Information Table 128. Heron Therapeutics Business Overview Table 129. Heron Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 131. Heron Therapeutics Recent Development Table 132. Glenmark Company Information Table 133. Glenmark Business Overview Table 134. Glenmark NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Glenmark NK1/NK3 Receptor Antagonists Product Portfolio Table 136. Glenmark Recent Development Table 137. North America NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 138. North America NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 139. North America NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 140. North America NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 141. North America NK1/NK3 Receptor Antagonists Sales Price by Type (2021-2026) & (USD/unit) Table 142. North America NK1/NK3 Receptor Antagonists Sales Price by Type (2027-2032) & (USD/unit) Table 143. North America NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 144. North America NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 145. North America NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 146. North America NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 147. North America NK1/NK3 Receptor Antagonists Sales Price by Application (2021-2026) & (USD/unit) Table 148. North America NK1/NK3 Receptor Antagonists Sales Price by Application (2027-2032) & (USD/unit) Table 149. North America NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 151. North America NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 152. North America NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 153. North America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 154. North America NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 155. North America NK1/NK3 Receptor Antagonists Sales Price by Country (2021-2026) & (USD/unit) Table 156. North America NK1/NK3 Receptor Antagonists Sales Price by Country (2027-2032) & (USD/unit) Table 157. United States NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 158. Canada NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 159. Mexico NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 160. Europe NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 161. Europe NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 162. Europe NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 163. Europe NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 164. Europe NK1/NK3 Receptor Antagonists Sales Price by Type (2021-2026) & (USD/unit) Table 165. Europe NK1/NK3 Receptor Antagonists Sales Price by Type (2027-2032) & (USD/unit) Table 166. Europe NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 167. Europe NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 168. Europe NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 169. Europe NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 170. Europe NK1/NK3 Receptor Antagonists Sales Price by Application (2021-2026) & (USD/unit) Table 171. Europe NK1/NK3 Receptor Antagonists Sales Price by Application (2027-2032) & (USD/unit) Table 172. Europe NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Europe NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 174. Europe NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 175. Europe NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 176. Europe NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 177. Europe NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 178. Europe NK1/NK3 Receptor Antagonists Sales Price by Country (2021-2026) & (USD/unit) Table 179. Europe NK1/NK3 Receptor Antagonists Sales Price by Country (2027-2032) & (USD/unit) Table 180. Germany NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 181. France NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 182. U.K. NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 183. Italy NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 184. Russia NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 185. Spain NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 186. Netherlands NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 187. Switzerland NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 188. Sweden NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 189. Poland NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 190. China NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 191. China NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 192. China NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 193. China NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 194. China NK1/NK3 Receptor Antagonists Sales Price by Type (2021-2026) & (USD/unit) Table 195. China NK1/NK3 Receptor Antagonists Sales Price by Type (2027-2032) & (USD/unit) Table 196. China NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 197. China NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 198. China NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 199. China NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 200. China NK1/NK3 Receptor Antagonists Sales Price by Application (2021-2026) & (USD/unit) Table 201. China NK1/NK3 Receptor Antagonists Sales Price by Application (2027-2032) & (USD/unit) Table 202. Asia NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 203. Asia NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 204. Asia NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 205. Asia NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 206. Asia NK1/NK3 Receptor Antagonists Sales Price by Type (2021-2026) & (USD/unit) Table 207. Asia NK1/NK3 Receptor Antagonists Sales Price by Type (2027-2032) & (USD/unit) Table 208. Asia NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 209. Asia NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 210. Asia NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 211. Asia NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 212. Asia NK1/NK3 Receptor Antagonists Sales Price by Application (2021-2026) & (USD/unit) Table 213. Asia NK1/NK3 Receptor Antagonists Sales Price by Application (2027-2032) & (USD/unit) Table 214. Asia NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 215. Asia NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 216. Asia NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 217. Asia NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 218. Asia NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 219. Asia NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 220. Asia NK1/NK3 Receptor Antagonists Sales Price by Country (2021-2026) & (USD/unit) Table 221. Asia NK1/NK3 Receptor Antagonists Sales Price by Country (2027-2032) & (USD/unit) Table 222. Japan NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 223. South Korea NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 224. India NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 225. Australia NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 226. Taiwan NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 227. Southeast Asia NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 228. SAMEA NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 229. SAMEA NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 230. SAMEA NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 231. SAMEA NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 232. SAMEA NK1/NK3 Receptor Antagonists Sales Price by Type (2021-2026) & (USD/unit) Table 233. SAMEA NK1/NK3 Receptor Antagonists Sales Price by Type (2027-2032) & (USD/unit) Table 234. SAMEA NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 235. SAMEA NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 236. SAMEA NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 237. SAMEA NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 238. SAMEA NK1/NK3 Receptor Antagonists Sales Price by Application (2021-2026) & (USD/unit) Table 239. SAMEA NK1/NK3 Receptor Antagonists Sales Price by Application (2027-2032) & (USD/unit) Table 240. SAMEA NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 241. SAMEA NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 242. SAMEA NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 243. SAMEA NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 244. SAMEA NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 245. SAMEA NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 246. SAMEA NK1/NK3 Receptor Antagonists Sales Price by Country (2021-2026) & (USD/unit) Table 247. SAMEA NK1/NK3 Receptor Antagonists Sales Price by Country (2027-2032) & (USD/unit) Table 248. Brazil NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 249. Argentina NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 250. Chile NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 251. Colombia NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 252. Peru NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 253. Saudi Arabia NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 254. Israel NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 255. UAE NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 256. Turkey NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 257. Iran NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 258. Egypt NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 259. Key Raw Materials Table 260. Raw Materials Key Suppliers Table 261. NK1/NK3 Receptor Antagonists Distributors List Table 262. NK1/NK3 Receptor Antagonists Customers List Table 263. Research Programs/Design for This Report Table 264. Authors List of This Report Table 265. Secondary Sources Table 266. Primary Sources List of Figures Figure 1. NK1/NK3 Receptor Antagonists Image Figure 2. Global NK1/NK3 Receptor Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK1/NK3 Receptor Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 4. NK1 Receptor Antagonist Image Figure 5. NK3 Receptor Antagonist Image Figure 6. Dual Antagonist Image Figure 7. Global NK1/NK3 Receptor Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global NK1/NK3 Receptor Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Specialty Clinic Image Figure 11. Global NK1/NK3 Receptor Antagonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 13. Global NK1/NK3 Receptor Antagonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2021-2032) Figure 16. Global NK1/NK3 Receptor Antagonists Sales (2021-2032) & (k units) Figure 17. Global NK1/NK3 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico NK1/NK3 Receptor Antagonists Sales YoY (2021-2032) & (k units) Figure 20. Europe NK1/NK3 Receptor Antagonists Sales YoY (2021-2032) & (k units) Figure 21. China NK1/NK3 Receptor Antagonists Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) NK1/NK3 Receptor Antagonists Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales YoY (2021-2032) & (k units) Figure 24. Global NK1/NK3 Receptor Antagonists Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global NK1/NK3 Receptor Antagonists Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global NK1/NK3 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2032) Figure 30. Global NK1/NK3 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2032) Figure 33. Global NK1/NK3 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2032) Figure 36. Global NK1/NK3 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2032) Figure 39. North America NK1/NK3 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 40. North America NK1/NK3 Receptor Antagonists Sales Share by Type (2021-2032) Figure 41. North America NK1/NK3 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 42. North America NK1/NK3 Receptor Antagonists Sales Share by Application (2021-2032) Figure 43. North America NK1/NK3 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 44. North America NK1/NK3 Receptor Antagonists Sales Share by Country (2021-2032) Figure 45. Europe NK1/NK3 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 46. Europe NK1/NK3 Receptor Antagonists Sales Share by Type (2021-2032) Figure 47. Europe NK1/NK3 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 48. Europe NK1/NK3 Receptor Antagonists Sales Share by Application (2021-2032) Figure 49. Europe NK1/NK3 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 50. Europe NK1/NK3 Receptor Antagonists Sales Share by Country (2021-2032) Figure 51. China NK1/NK3 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 52. China NK1/NK3 Receptor Antagonists Sales Share by Type (2021-2032) Figure 53. China NK1/NK3 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 54. China NK1/NK3 Receptor Antagonists Sales Share by Application (2021-2032) Figure 55. Asia NK1/NK3 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 56. Asia NK1/NK3 Receptor Antagonists Sales Share by Type (2021-2032) Figure 57. Asia NK1/NK3 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 58. Asia NK1/NK3 Receptor Antagonists Sales Share by Application (2021-2032) Figure 59. Asia NK1/NK3 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 60. Asia NK1/NK3 Receptor Antagonists Sales Share by Country (2021-2032) Figure 61. SAMEA NK1/NK3 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 62. SAMEA NK1/NK3 Receptor Antagonists Sales Share by Type (2021-2032) Figure 63. SAMEA NK1/NK3 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 64. SAMEA NK1/NK3 Receptor Antagonists Sales Share by Application (2021-2032) Figure 65. SAMEA NK1/NK3 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 66. SAMEA NK1/NK3 Receptor Antagonists Sales Share by Country (2021-2032) Figure 67. NK1/NK3 Receptor Antagonists Value Chain Figure 68. Manufacturing Cost Structure Figure 69. NK1/NK3 Receptor Antagonists Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • NK1 Receptor Antagonist
  • NK3 Receptor Antagonist
  • Dual Antagonist
Applications
  • Hospital
  • Specialty Clinic
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yichang Humanwell Pharmaceutical
  • Qilu Pharmaceutical
  • Merck
  • Luoxin Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Helsinn Healthcare
  • Hansoh Pharma
  • Fresenius Kabi
  • Beijing Sihuan Pharmaceutical
  • Bayer
  • Astellas
  • Torrent Pharmaceuticals
  • TerSera Therapeutics
  • Heron Therapeutics
  • Glenmark

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 NK1/NK3 Receptor Antagonists Market by Type
  3. 1.2.1 Global NK1/NK3 Receptor Antagonists Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NK1 Receptor Antagonist
  5. 1.2.3 NK3 Receptor Antagonist
  6. 1.2.4 Dual Antagonist
  7. 1.3 NK1/NK3 Receptor Antagonists Market by Application
  8. 1.3.1 Global NK1/NK3 Receptor Antagonists Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Specialty Clinic
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 NK1/NK3 Receptor Antagonists Market Dynamics
  1. 2.1 NK1/NK3 Receptor Antagonists Industry Trends
  2. 2.2 NK1/NK3 Receptor Antagonists Industry Drivers
  3. 2.3 NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 NK1/NK3 Receptor Antagonists Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global NK1/NK3 Receptor Antagonists Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global NK1/NK3 Receptor Antagonists Revenue by Region
  3. 3.2.1 Global NK1/NK3 Receptor Antagonists Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global NK1/NK3 Receptor Antagonists Revenue by Region (2021-2026)
  5. 3.2.3 Global NK1/NK3 Receptor Antagonists Revenue by Region (2027-2032)
  6. 3.2.4 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2021-2032)
  7. 3.3 Global NK1/NK3 Receptor Antagonists Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global NK1/NK3 Receptor Antagonists Sales by Region
  9. 3.4.1 Global NK1/NK3 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026)
  11. 3.4.3 Global NK1/NK3 Receptor Antagonists Sales by Region (2027-2032)
  12. 3.4.4 Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global NK1/NK3 Receptor Antagonists Revenue by Manufacturers
  2. 4.1.1 Global NK1/NK3 Receptor Antagonists Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global NK1/NK3 Receptor Antagonists Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global NK1/NK3 Receptor Antagonists Sales by Manufacturers
  6. 4.2.1 Global NK1/NK3 Receptor Antagonists Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global NK1/NK3 Receptor Antagonists Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global NK1/NK3 Receptor Antagonists Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global NK1/NK3 Receptor Antagonists Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global NK1/NK3 Receptor Antagonists Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global NK1/NK3 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global NK1/NK3 Receptor Antagonists Manufacturers, Product Type & Application
  13. 4.7 Global NK1/NK3 Receptor Antagonists Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global NK1/NK3 Receptor Antagonists Market CR5 and HHI
  16. 4.8.2 2025 NK1/NK3 Receptor Antagonists Tier 1, Tier 2, and Tier 3
5 NK1/NK3 Receptor Antagonists Market by Type
  1. 5.1 Global NK1/NK3 Receptor Antagonists Revenue by Type
  2. 5.1.1 Global NK1/NK3 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2032)
  5. 5.2 Global NK1/NK3 Receptor Antagonists Sales by Type
  6. 5.2.1 Global NK1/NK3 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2032)
  9. 5.3 Global NK1/NK3 Receptor Antagonists Price by Type
6 NK1/NK3 Receptor Antagonists Market by Application
  1. 6.1 Global NK1/NK3 Receptor Antagonists Revenue by Application
  2. 6.1.1 Global NK1/NK3 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2032)
  5. 6.2 Global NK1/NK3 Receptor Antagonists Sales by Application
  6. 6.2.1 Global NK1/NK3 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2032)
  9. 6.3 Global NK1/NK3 Receptor Antagonists Price by Application
7 Company Profiles
  1. 7.1 Chia Tai Tianqing Pharmaceutical
  2. 7.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 7.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 7.1.3 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  6. 7.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 7.2 Yichang Humanwell Pharmaceutical
  8. 7.2.1 Yichang Humanwell Pharmaceutical Company Information
  9. 7.2.2 Yichang Humanwell Pharmaceutical Business Overview
  10. 7.2.3 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  12. 7.2.5 Yichang Humanwell Pharmaceutical Recent Developments
  13. 7.3 Qilu Pharmaceutical
  14. 7.3.1 Qilu Pharmaceutical Company Information
  15. 7.3.2 Qilu Pharmaceutical Business Overview
  16. 7.3.3 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  18. 7.3.5 Qilu Pharmaceutical Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck NK1/NK3 Receptor Antagonists Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Luoxin Pharmaceutical
  26. 7.5.1 Luoxin Pharmaceutical Company Information
  27. 7.5.2 Luoxin Pharmaceutical Business Overview
  28. 7.5.3 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  30. 7.5.5 Luoxin Pharmaceutical Recent Developments
  31. 7.6 Jiangsu Hengrui Pharmaceuticals
  32. 7.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 7.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 7.6.3 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  36. 7.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 7.7 Helsinn Healthcare
  38. 7.7.1 Helsinn Healthcare Company Information
  39. 7.7.2 Helsinn Healthcare Business Overview
  40. 7.7.3 Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio
  42. 7.7.5 Helsinn Healthcare Recent Developments
  43. 7.8 Hansoh Pharma
  44. 7.8.1 Hansoh Pharma Company Information
  45. 7.8.2 Hansoh Pharma Business Overview
  46. 7.8.3 Hansoh Pharma NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio
  48. 7.8.5 Hansoh Pharma Recent Developments
  49. 7.9 Fresenius Kabi
  50. 7.9.1 Fresenius Kabi Company Information
  51. 7.9.2 Fresenius Kabi Business Overview
  52. 7.9.3 Fresenius Kabi NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio
  54. 7.9.5 Fresenius Kabi Recent Developments
  55. 7.10 Beijing Sihuan Pharmaceutical
  56. 7.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 7.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 7.10.3 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  60. 7.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 7.11 Bayer
  62. 7.11.1 Bayer Company Information
  63. 7.11.2 Bayer Business Overview
  64. 7.11.3 Bayer NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Bayer NK1/NK3 Receptor Antagonists Product Portfolio
  66. 7.11.5 Bayer Recent Developments
  67. 7.12 Astellas
  68. 7.12.1 Astellas Company Information
  69. 7.12.2 Astellas Business Overview
  70. 7.12.3 Astellas NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Astellas NK1/NK3 Receptor Antagonists Product Portfolio
  72. 7.12.5 Astellas Recent Developments
  73. 7.13 Torrent Pharmaceuticals
  74. 7.13.1 Torrent Pharmaceuticals Company Information
  75. 7.13.2 Torrent Pharmaceuticals Business Overview
  76. 7.13.3 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  78. 7.13.5 Torrent Pharmaceuticals Recent Developments
  79. 7.14 TerSera Therapeutics
  80. 7.14.1 TerSera Therapeutics Company Information
  81. 7.14.2 TerSera Therapeutics Business Overview
  82. 7.14.3 TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  84. 7.14.5 TerSera Therapeutics Recent Developments
  85. 7.15 Heron Therapeutics
  86. 7.15.1 Heron Therapeutics Company Information
  87. 7.15.2 Heron Therapeutics Business Overview
  88. 7.15.3 Heron Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  90. 7.15.5 Heron Therapeutics Recent Developments
  91. 7.16 Glenmark
  92. 7.16.1 Glenmark Company Information
  93. 7.16.2 Glenmark Business Overview
  94. 7.16.3 Glenmark NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Glenmark NK1/NK3 Receptor Antagonists Product Portfolio
  96. 7.16.5 Glenmark Recent Developments
8 North America
  1. 8.1 North America NK1/NK3 Receptor Antagonists Market Size by Type
  2. 8.1.1 North America NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032)
  3. 8.1.2 North America NK1/NK3 Receptor Antagonists Sales by Type (2021-2032)
  4. 8.1.3 North America NK1/NK3 Receptor Antagonists Price by Type (2021-2032)
  5. 8.2 North America NK1/NK3 Receptor Antagonists Market Size by Application
  6. 8.2.1 North America NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032)
  7. 8.2.2 North America NK1/NK3 Receptor Antagonists Sales by Application (2021-2032)
  8. 8.2.3 North America NK1/NK3 Receptor Antagonists Price by Application (2021-2032)
  9. 8.3 North America NK1/NK3 Receptor Antagonists Market Size by Country
  10. 8.3.1 North America NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America NK1/NK3 Receptor Antagonists Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe NK1/NK3 Receptor Antagonists Market Size by Type
  2. 9.1.1 Europe NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032)
  3. 9.1.2 Europe NK1/NK3 Receptor Antagonists Sales by Type (2021-2032)
  4. 9.1.3 Europe NK1/NK3 Receptor Antagonists Price by Type (2021-2032)
  5. 9.2 Europe NK1/NK3 Receptor Antagonists Market Size by Application
  6. 9.2.1 Europe NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032)
  7. 9.2.2 Europe NK1/NK3 Receptor Antagonists Sales by Application (2021-2032)
  8. 9.2.3 Europe NK1/NK3 Receptor Antagonists Price by Application (2021-2032)
  9. 9.3 Europe NK1/NK3 Receptor Antagonists Market Size by Country
  10. 9.3.1 Europe NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe NK1/NK3 Receptor Antagonists Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China NK1/NK3 Receptor Antagonists Market Size by Type
  2. 10.1.1 China NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032)
  3. 10.1.2 China NK1/NK3 Receptor Antagonists Sales by Type (2021-2032)
  4. 10.1.3 China NK1/NK3 Receptor Antagonists Price by Type (2021-2032)
  5. 10.2 China NK1/NK3 Receptor Antagonists Market Size by Application
  6. 10.2.1 China NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032)
  7. 10.2.2 China NK1/NK3 Receptor Antagonists Sales by Application (2021-2032)
  8. 10.2.3 China NK1/NK3 Receptor Antagonists Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia NK1/NK3 Receptor Antagonists Market Size by Type
  2. 11.1.1 Asia NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032)
  3. 11.1.2 Asia NK1/NK3 Receptor Antagonists Sales by Type (2021-2032)
  4. 11.1.3 Asia NK1/NK3 Receptor Antagonists Price by Type (2021-2032)
  5. 11.2 Asia NK1/NK3 Receptor Antagonists Market Size by Application
  6. 11.2.1 Asia NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032)
  7. 11.2.2 Asia NK1/NK3 Receptor Antagonists Sales by Application (2021-2032)
  8. 11.2.3 Asia NK1/NK3 Receptor Antagonists Price by Application (2021-2032)
  9. 11.3 Asia NK1/NK3 Receptor Antagonists Market Size by Country
  10. 11.3.1 Asia NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia NK1/NK3 Receptor Antagonists Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA NK1/NK3 Receptor Antagonists Market Size by Type
  2. 12.1.1 SAMEA NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA NK1/NK3 Receptor Antagonists Sales by Type (2021-2032)
  4. 12.1.3 SAMEA NK1/NK3 Receptor Antagonists Price by Type (2021-2032)
  5. 12.2 SAMEA NK1/NK3 Receptor Antagonists Market Size by Application
  6. 12.2.1 SAMEA NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA NK1/NK3 Receptor Antagonists Sales by Application (2021-2032)
  8. 12.2.3 SAMEA NK1/NK3 Receptor Antagonists Price by Application (2021-2032)
  9. 12.3 SAMEA NK1/NK3 Receptor Antagonists Market Size by Country
  10. 12.3.1 SAMEA NK1/NK3 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA NK1/NK3 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA NK1/NK3 Receptor Antagonists Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 NK1/NK3 Receptor Antagonists Value Chain Analysis
  2. 13.1.1 NK1/NK3 Receptor Antagonists Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 NK1/NK3 Receptor Antagonists Production Mode & Process
  6. 13.2 NK1/NK3 Receptor Antagonists Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 NK1/NK3 Receptor Antagonists Distributors
  9. 13.2.3 NK1/NK3 Receptor Antagonists Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst